Project Details
Description
A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma
| Status | Active |
|---|---|
| Effective start/end date | 7/16/19 → 7/31/24 |
Funding
- ADC THERAPEUTICS SA
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.